Cyclophosphamide (generic), Cytoxan

Cyclophosphamide (generic), Cytoxan Newswire (Page 3)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 3)

Results 41 - 60 of 285 in Cyclophosphamide (generic), Cytoxan

  1. CORRECT: Amgen shares fall after-hours on disappointing trial dataRead the original story w/Photo

    Aug 13, 2014 | MarketWatch

    Amgen said a Phase 3 FOCUS trial of Kyprolis, compared with an active control regimen of low-dose steroids plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma, failed to meet its primary endpoint of improving overall survival.

    Comment?

  2. Findings from Ghent University Update Understanding of Gene Therapy...Read the original story

    Aug 13, 2014 | Hispanic Business

    Editor at Cancer Vaccine Week -- A new study on Biotechnology is now available. According to news reporting originating in Ghent, , by NewsRx journalists, research stated, "In this work a combination therapy that acts upon the immune suppressive, the innate and specific arms of the immune system is proposed.

    Comment?

  3. Researchers Submit Patent Application, 'Salts and Crystalline Forms...Read the original story

    Aug 13, 2014 | Hispanic Business

    News editors obtained the following quote from the background information supplied by the inventors: "Overexpression of Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.

    Comment?

  4. Breast Cancer Chemotherapy Varies Widely: Study Raises Questions About Early Treatment ChoicesRead the original story w/Photo

    Aug 13, 2014 | Forbes.com

    Last month, the Journal of Clinical Oncology reported that six chemotherapy regimens commonly given to patients with early-stage breast cancer vary widely in their side effects.

    Comment?

  5. Real world costs and cost-effectiveness of Rituximab for diffuse...Read the original story

    Aug 12, 2014 | BioMed Central

    Current treatment of diffuse-large-B-cell lymphoma includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.

    Comment?

  6. Cyclophosphamide TabletsRead the original story

    Aug 11, 2014 | ASHP

    Cyclophosphamide tablets, Roxane 25 mg, 100 count - discontinued 50 mg, 100 count - discontinued August 11, 2014, University of Utah, Drug Information Service.

    Comment?

  7. Eradication of bone marrow minimal residual disease may prompt early...Read the original story

    Aug 8, 2014 | CiteULike

    The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab begs the question of the value of minimal residual disease -negative status as a treatment end point.

    Comment?

  8. Study Findings on Peptides and Proteins Are Outlined in Reports from...Read the original story

    Aug 6, 2014 | Hispanic Business

    The objective of the study was to develop theranostic nanovehicles capable of a) targeting cerebrovascular amyloid; b) providing magnetic resonance imaging contrast for the early detection of CAA; and c) treating cerebrovascular inflammation resulting from CAA."

    Comment?

  9. Research Conducted at Fred Hutchinson Cancer Research Center Has...Read the original story

    Aug 6, 2014 | Hispanic Business

    We tested the hypothesis that reversing the sequence of administration BU/CY to CY/ BU) would reduce SOS and day +100 nonrelapse mortality."

    Comment?

  10. ChemoCentryx's (CCXI) Tom Schall on Q2 2014 Results - Earnings Call TranscriptRead the original story

    Aug 5, 2014 | Seeking Alpha

    Welcome to the ChemoCentryx Second Quarter 2014 Financial Results Conference Call.

    Comment?

  11. Study identifies genetic variants linked with severe skin reactions to antiepileptic drugRead the original story

    Aug 5, 2014 | PhysOrg Weblog

    Researchers have identified genetic variants that are associated with severe adverse skin reactions to the antiepileptic drug phenytoin, according to a study in the August 6 issue of JAMA .

    Comment?

  12. ChemoCentryx, Inc. Announces Financial Results For The Second Quarter Ended June 30, 2014Read the original story

    Aug 5, 2014 | BioSpace

    ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the second quarter ended June 30, 2014.

    Comment?

  13. Cytotoxicity of some Russian ethnomedicinal plants and plant compounds.Read the original story

    Aug 3, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  14. OBI Pharma Announces Completion of Patient Enrollment in Phase...Read the original story

    Aug 1, 2014 | PRWeb

    OBI Pharma, Inc., a Taiwan biotech company , announced that it has completed patient enrollment in its Phase 2/3 clinical trial evaluating the safety and efficacy of its lead compound, OBI-822, an active immunotherapy for the treatment of metastatic breast cancer.

    Comment?

  15. Type of lymphoma treatment impacts degree of harm to spermRead the original story w/Photo

    Jul 28, 2014 | PhysOrg Weblog

    Lymphoma treatment has damaging effects on spermatogenesis but, in most patients, sperm production recovers within two years post-treatment, according to a study published online July 17 in Fertility and Sterility .

    Comment?

  16. Study Results from German Cancer Research Center Provide New Insights ...Read the original story

    Jul 23, 2014 | Hispanic Business

    Editor at Clinical Oncology Week -- Current study results on Biotechnology have been published.

    Comment?

  17. National Pharmaceutical Pricing Authority moves to bring cancer drugs under price controlRead the original story w/Photo

    Jul 21, 2014 | DNA India

    Sets July 24 deadline for six pharma firms to submit pricing data of their cancer drugs, pulls them up for dithering to furnish pricing data The National Pharmaceutical Pricing Authority is moving fast on reducing prices of cancer drugs.

    Comment?

  18. Evaluation of toxicities from combined metronomic and...Read the original story

    Jul 19, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  19. Why the Market is Wrong About Baxter StockRead the original story

    Jul 18, 2014 | The Motley Fool

    Analysts continue to fret that ) will grab considerable market share in hemophilia and that generic competition for other products will add to the revenue erosion.

    Comment?

  20. UPDATE 2-Gambro acquisition boosts Baxter's salesRead the original story

    Jul 17, 2014 | Reuters

    Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

    Comment?